Icosavax Funding & Investors
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle.
icosavax.comTotal Amount Raised: $235,300,000
Icosavax Funding Rounds
Post Ipo Equity
$67,800,000
Post Ipo Equity Investors
Logos CapitalVivo CapitalTCG CrossoverSeries B
$100,000,000
Series B Investors
Viking Global InvestorsAdams Street PartnersCormorant Asset ManagementPerceptive AdvisorsOmega FundsSanofi VenturesHenderson Global InvestorsQiming Venture Partners USARA Capital ManagementNanoDimensionOpen Philanthropy ProjectSurveyor CapitalGrant
$10,000,000
Grant Investors
Gates FoundationGrant
$6,500,000
Grant Investors
Good VenturesSeries A
$51,000,000
Series A Investors
Adams Street PartnersSanofi VenturesQiming Venture Partners USASANOFINanoDimension
Funding info provided by Diffbot.